Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (3092)	5/22/1999 7:04:00 PM
From: Terry D.	Read Replies (1) \| Respond to of 3702

Our 10 month man. RESPONSE OF HORMONALLY REFRACTORY PROSTATE CANCER (HRPC) TO TNT-1 MONOCLONAL ANTIBODY Stephen B. Strum, Alan Epstein, Clive Taylor, Laura Thompson & Stan Mills Culver City, Ca , LAC- USC Medical Center, Los Angeles, Ca & U of Oklahoma, Oklahoma City, Okla. Treatment options for HRPC are severely limited with responses to current chemotherapy regimens usually being of short duration. TNT-1 is a murine monoclonal antibody which has been shown to bind specifically to degenerating and dead cells of human cancers (Epstein et al, Cancer Res. 48:5842-5848, 1988). The antibody recognizes an antigenic domain of nuclear histones which is expressed in all cancers and normal tissues studied to date. Inadequate blood supply and impaired phagocytic responses within the tumor favor the accumulation of degenerating cells adjacent to viable areas of the tumor. In contrast, normal tissues have a relatively low rate of cell death and are characterized by a rapid and orderly removal of necrotic elements. We report successful treatment with TNT-1 MoAb in a 47 year old man with HRPC with prior treatment that included orchiectomy, flutamide, suramin, radiation therapy and doxorubicin. Within 36 days after the administration of 50 mg of biotinylated TNT-1 followed by 20 millicuries of I-131- streptavidin given weekly times 2, the PSA declined from 210 to 4.9 and the PAP from 6.5 to 1.2. The patient was clinically improved and remained stable for 10 months having received only TNT-1 for 2 such treatment cycles. Moderate thrombocytopenia and leukopenia with nadirs at day 36 after treatment were noted. Further clinical evaluation of TNT-1 against a broad spectrum of tumor types is now being considered. rattler.cameron.edu